Estuary Biotherapeutics
Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.
$93MSeries A
Participant4C
4BIO Capital
Activity from announced rounds
Activity in this selectionUnited States · Oct 19, 2026 · Sep 20, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $93M 1 disclosed · full round size, not this investor’s share